Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | ACP3 | P15309 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7871934 | 0.77 | ACP3 (0.44) | METAP2METAP1ACP3SSTR4 | |
| SCHEMBL1762200 | 0.72 | KCNA5 (0.58) | METAP2METAP1ACP3HSD11B1HCRTR1 | |
| SCHEMBL3574304 | 0.72 | KCNA5 (0.58) | METAP2METAP1ACP3HSD11B1HCRTR1 | |
| SCHEMBL1762342 | 0.72 | KCNA5 (0.58) | METAP2METAP1ACP3HSD11B1HCRTR1 | |
| Hydrochloric Acid SCHEMBL1762465 | 0.72 | KCNA5 (0.57) | METAP2METAP1ACP3HSD11B1 | |
| Hydrochloric Acid SCHEMBL1762349 | 0.72 | KCNA5 (0.57) | METAP2METAP1ACP3HSD11B1 | |
| SCHEMBL28676012 | 0.70 | ALDH1A1 (0.39) | SSTR4HSD11B1 | |
| SCHEMBL6908002 | 0.69 | CA1 (0.45) | POLBPKMSMN1; SMN2NPSR1 | |
| SCHEMBL7590749 | 0.69 | POLB (0.55) | POLBPKMSMN1; SMN2NPSR1 | |
| SCHEMBL7882637 | 0.68 | KCNA5 (0.57) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160008322-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP (CA) | 2016-01-14 | — | — | US | disclosed |
| US-20140314685-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20130171077-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2013-07-04 | — | — | US | disclosed |
| US-8008342-B2 | Ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2011-08-30 | — | — | US | disclosed |
| US-20110207730-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2011-08-25 | — | — | US | disclosed |
| US-7875611-B2 | (+)-trans-[2-(4-morpholinyl)-1-[2-(2-naphthoxy)ethoxy)]; (1R,2R)/(1S,2S)-2-[1,4-dioxa-7-azaspiro[4.4]non-7-yl]-1-(1-naphthenethoxy)cyclohexanecyclohexane; treatment of arrhythmia and the production of analgesia and local anesthesia | CARDIOME PHARMA CORP. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-20100056603-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2010-03-04 | — | — | US | disclosed |
| US-20100029639-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2010-02-04 | — | — | US | disclosed |
| US-7534790-B2 | Ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2009-05-19 | — | — | US | disclosed |
| US-7524879-B2 | Ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2009-04-28 | — | — | US | disclosed |
| US-20070190156-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2007-08-16 | — | — | US | disclosed |
| US-20070004718-A1 | Ion channel modulating compounds and uses thereof | CARDIOME PHAMA CORP. (CA) | 2007-01-04 | — | — | US | disclosed |
| US-7101877-B2 | Ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2006-09-05 | — | — | US | disclosed |
| US-20060189677-A1 | Treatment of arrhythmia and the production of analgesia and local anesthesia by administering 1-[2-(3,4-dimethoxyphenyl)ethoxy]-2-(3-hydroxy-1-pyrrolidinyl)cyclohexane or a salt | CARDIOME PHARMA CORP. (CA) | 2006-08-24 | — | — | US | disclosed |
| US-7057053-B2 | for treatment of arrhythmia and the production of analgesia and local anesthesia | CARDIOME PHARMA CORP. (CA) | 2006-06-06 | — | — | US | disclosed |
| US-20050209307-A1 | Cardiovascular disorders; antiarrhythmia agents as result od analgesics, anesthetics | CARDIOME PHARMA CORP. (CA) | 2005-09-22 | — | — | US | disclosed |
| US-20050192208-A2 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2005-09-01 | — | — | US | disclosed |
| US-20050020481-A1 | Ion channel modulating compounds and uses thereof | BAIN ALLAN I (CA) | 2005-01-27 | — | — | US | disclosed |
| EP-1422217-A2 | Aminocyclohexyl ether compounds and uses thereof | Cardiome Pharma Corp. (CA) | 2004-05-26 | — | — | EP | disclosed |
| EP-1087934-B1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | NORTRAN PHARMACEUTICALS INC (CA) | 2004-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171077-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | POLB 4656/4885PKM 1912/4885SMN1; SMN2 2646/4885 |
| US-20110207730-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | POLB 4656/4885PKM 1912/4885SMN1; SMN2 2646/4885 |
| US-20050020481-A1 | Ion channel modulating compounds and uses thereof | TRPV1, TRPA1, KCNN2 | POLB 4656/4885PKM 1912/4885SMN1; SMN2 2646/4885 |
| US-20100056603-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | POLB 4656/4885PKM 1912/4885SMN1; SMN2 2646/4885 |
| US-20070004718-A1 | Ion channel modulating compounds and uses thereof | TRPV1, TRPA1, KCNN2 | POLB 4656/4885PKM 1912/4885SMN1; SMN2 2646/4885 |
| US-20050209307-A1 | Cardiovascular disorders; antiarrhythmia agents as result od analgesics, anesthetics | KCNH1, TRPV1, KCNH2 | POLB 3438/4885PKM 1416/4885SMN1; SMN2 1652/4885 |
| US-20160008322-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | POLB 4656/4885PKM 1912/4885SMN1; SMN2 2646/4885 |
| US-20070190156-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | POLB 4656/4885PKM 1912/4885SMN1; SMN2 2646/4885 |
| US-20140314685-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | POLB 4656/4885PKM 1912/4885SMN1; SMN2 2646/4885 |
| US-20060189677-A1 | Treatment of arrhythmia and the production of analgesia and local anesthesia by administering 1-[2-(3,4-dimethoxyphenyl)ethoxy]-2-(3-hydroxy-1-pyrrolidinyl)cyclohexane or a salt | KCNN2, KCNN3, KCNN1 | POLB 3778/4885PKM 1536/4885SMN1; SMN2 2072/4885 |
| US-20050192208-A2 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | POLB 4737/4885PKM 1704/4885SMN1; SMN2 2234/4885 |
| US-20100029639-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | POLB 4656/4885PKM 1912/4885SMN1; SMN2 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.